CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?

Abstract

Chimeric antigen receptor (CAR) modified T cells have emerged as powerful tools for controlling leukemias. We recently showed that anti-CD123 CAR-expressing cytokine-induced killer T cell treatment is an effective immunotherapeutic approach to eradicate Acute Myeloid Leukemia (AML) cells. Here, we discuss how this genetically modified cellbased strategy could be relevant to the field of AML therapeutics. © 2014 Landes Bioscience.